Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices after successfully passing […]
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) — – Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of […]
Year-end highlights include three record product orders and $6.8M in expense reductioneffectively positioning the Company for long-term growth WICHITA, Kan., […]